证券代码：603718 证券简称：海利生物 公告编号：2026－005 上海海利生物技术股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计公司 2025 年度实现利润总额 3,400 万元到 4,000 万元，实现归属于母公司所有者的净利润 1,100 万元到 1,600 万元，归属 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额：208,117,455.78 元。归属于母公司股东的净利润： 171,180,295.61 元。归属于母公司股东的扣除非经常性损益的净利润： 10,581,377.63 元。 （二）每股收益：0.26 元。（以最新股本 651,904,700 股计算） （三）营业收入：271,039,818.26 元。 三、本期业绩下滑的主要原因 1、2024 年公司因出 ...

证券代码：688601 证券简称：力芯微 公告编号：2026-001 无锡力芯微电子股份有限公司 2025 年年度业绩预告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 经无锡力芯微电子股份有限公司（以下简称"公司"）财务部门初步测算： 上年同期公司实现营业收入 78,749.33 万元，归属于母公司所有者的净利润 12,585.74 万元，归属于母公司所有者的扣除非经常性损益的净利润 10,496.84 万 元，每股收益 0.94 元。 三、本期业绩变化的主要原因 （一）主营业务影响。 1 公司受外部市场需求疲软、供应链成本波动及行业竞争加剧等因素影响，虽 然报告期内销售量较上年有增长，但毛利率较上年同期有所下降，营业收入也略 降 2.41%左右。另，公司在技术研发与市场布局上持续投入，导致归属于母公司 所有者的净利润及扣除非经常性损益的净利润减少较多。 面对短周期调整，我们始终 ...

Financial Performance Expectations - The company expects a net loss for the fiscal year 2025, with projected losses ranging from 95 million to 115 million yuan, compared to a profit of 35.54 million yuan in the same period last year[2][3]. - The net profit after deducting non-recurring gains and losses is expected to be a loss between 92 million and 109 million yuan, down from a profit of 29.68 million yuan year-over-year[3]. - Basic earnings per share are projected to be a loss between 0.6685 yuan and 0.8092 yuan, compared to earnings of 0.2480 yuan per share in the previous year[3]. - The financial data presented is a forecast and has not been audited; actual figures will be disclosed in the 2025 annual report[7]. Operational Strategy - The company plans to maintain a full industry chain operation in pig farming, with an estimated feed sales volume of approximately 6.5 million tons in 2025[5]. - The average selling price of commercial pigs is expected to be around 13.36 yuan per kilogram, reflecting a year-over-year decline of approximately 18.61%[5]. - The company has faced challenges in achieving expected production capacity utilization in its own fattening pig farms due to the purchase of high-priced piglets for fattening[5]. - The company has made provisions for inventory impairment on biological assets due to the decline in pig prices, in accordance with accounting standards and prudence principles[5]. Risk Factors - Risks include significant fluctuations in pig market prices, feed raw material prices, outbreaks of animal diseases, changes in environmental policies, and food safety issues, which may impact operational performance[6].

证券代码：000990 证券简称：诚志股份 公告编号：2026-002 诚志股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日—2025 年 12 月 31 日 | 项 | 目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 亏损：10,000 | 万元-5,000 | 万元 | 盈利：23,058.89 | 万元 | | | | 与上年同期下降：143.37%-121.68% | | | | | | 扣除非经常性损 益后的净利润 | | 盈利：1,350 | 万元-2,000 | 万元 | 盈利：22,678.64 | 万元 | | | | 与上年同期下降：94.05%-91.18% | | | | | | 基本每股收益 | | 亏损：0.0823 | 元/股—0.0412 | 元/股 | 盈利：0.1897 | 元/股 | 公司已就 ...

Financial Performance - The company expects a net profit attributable to shareholders of between 90 million and 130 million yuan for the year 2025, marking a turnaround from a loss in the previous year[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 50 million and 70 million yuan for 2025[4]. - In the previous year, the company reported a net loss attributable to shareholders of 151.42 million yuan and a total profit of -164.25 million yuan[5]. - The earnings forecast indicates a significant improvement compared to the previous year's performance, reflecting a strategic shift in operations[4]. Asset Management - The company has reduced asset impairment losses compared to the previous year, contributing to the expected profit[7]. Market Strategy - The company has strengthened its domestic and international market expansion, enhancing brand development and online business growth, leading to stable revenue growth[7]. Earnings Forecast - The earnings forecast is based on preliminary calculations and has not been audited, with final figures to be confirmed in the audited annual report[9]. - There is uncertainty regarding the final compensation amount for accounts receivable from CVB, Inc., which may affect the earnings forecast[8]. - The company has communicated with its auditors regarding the uncertainties and currently does not foresee major discrepancies[8]. - Investors are advised to be cautious of potential risks that may impact the accuracy of the earnings forecast[8].

1、业绩预告期间：2025年01月01日至2025年12月31日 证券代码：000735 证券简称：罗牛山 公告编号：2026-003 罗牛山股份有限公司 2025 年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 | | | | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 盈利：14,000 | 万元-18,000 | 万元 | 盈利：24,175.52 | | | | | 比上年同期下降： | | | | 万元 | | | | 25.54%-42.09% | | | | | | 扣除非经常性损 益后的净利润 | | 盈利：23,000 | 万元-27,000 | 万元 | 盈利：27,591.55 | 万元 | | | | 比上年同期下降： | | | | | | | | 2.14%-16.64% | | | | | | 基本每股收益 | | 盈利: 0.1216 | 元/股-0. ...

证券代码：688199 证券简称：久日新材 公告编号：2026-006 天津久日新材料股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1.经天津久日新材料股份有限公司（以下简称公司）财务部门初步测算，预 计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据）相 比，将实现扭亏为盈，实现归属于母公司所有者的净利润为2,100.00万元到 3,150.00万元。 2.预计2025年年度实现归属于母公司所有者扣除非经常性损益后的净利润 为1,440.00万元到2,160.00万元。 （三）本期业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 2024 年年度公司利润总额：-4,314.47 万元；归属于母公司所有者的净利润： -5,376.08 万元；归属于母公司所有者的扣除非经常性损益的净利润：-6,278.48 万元；每股收益：-0.33 元。 三 ...

证券代码：002436 证券简称： 兴森科技 公告编号：2026-01-002 深圳市兴森快捷电路科技股份有限公司 2025 年年度业绩预告 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日 2、预计的经营业绩：扭亏为盈 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：13,200万元–14,000万元 | 亏损：19,828.98万元 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 盈利：13,800万元–14,600万元 | 亏损：19,576.85万元 | | 基本每股收益 | 盈利：0.08元/股–0.08元/股 | 亏损：0.12元/股 | 二、与会计师事务所沟通情况 公司已就本次业绩预告情况与年报审计会计师事务所进行预沟通，公司与会 计师事务所对本次业绩预告不存在分歧。 本次业绩预告相关财务数据未经审计机构预审计。 三、业绩变动原因说明 受益于行业复苏，公司营业收入保持稳定增长。利 ...

Financial Performance - The company expects a net profit attributable to shareholders of between 45 million and 67.5 million yuan, representing a year-on-year increase of 309.36% to 414.04%[3] - The net profit after deducting non-recurring gains and losses is projected to be between 46 million and 69 million yuan, indicating a year-on-year growth of 264.29% to 346.43%[3] - Basic earnings per share are estimated to be between 0.2844 yuan and 0.4266 yuan, compared to a loss of 0.1400 yuan per share in the previous year[3] Business Strategy - The company has focused on a "self-owned brand + exclusive agency brand" development strategy, leading to significant revenue growth from key brands like X-BIONIC and others[5] - The company has seen substantial improvements in revenue and profitability due to ongoing product development and brand marketing efforts across multiple sales channels[5] Performance Forecast - The performance forecast is based on preliminary estimates and has not been audited by the accounting firm, with final figures to be confirmed in the annual report[4][6] - The performance period for the forecast is from January 1, 2025, to December 31, 2025, indicating a turnaround from previous losses[9]

Financial Performance Projections - The estimated net profit for 2025 is projected to be between 2,000 and 3,000 million CNY, representing a decline of over 50% compared to the previous year[2] - The net profit attributable to shareholders is expected to decrease by approximately 87.89% to 16,517.97 million CNY from the previous year[3] - The net profit after deducting non-recurring gains and losses is forecasted to be between 2,500 and 3,750 million CNY, reflecting a decline of about 82.90% compared to last year[3] - The basic earnings per share is anticipated to be between 0.0066 and 0.0099 CNY, down from 0.0544 CNY in the previous year[3] Factors Affecting Performance - The decline in performance is primarily attributed to a decrease in sales scale, reduced transferable area, and a drop in operating income[5] - The company has adjusted its sales policies, leading to a decrease in product prices and a declining gross profit margin[5] - The company plans to recognize impairment provisions for certain real estate projects showing signs of impairment[5] Financial Data Disclosure - The data presented is a preliminary estimate and has not been audited by the accounting firm[4] - Investors are advised to be cautious as the actual financial data will be disclosed in the 2025 annual report[6] - The company has communicated with the accounting firm regarding the performance forecast, and there are no discrepancies[4]